Effects of Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion and energy balance in human obesity and diabetes

Record Provided by the NHSTCT Register - 2006 Update - Department of Health0 个研究点目标入组 6 人开始时间: 2006年9月29日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Obese male subjects between age 20-60 years will be recruited by advertisement and by invitation of eligible patients who have already undergone glucose tolerance testing. This is a pilot study and will involve the following groups. 6 lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance and 6 obese (BMI >30 kg/m2) type-2 diabetic patients on treatment with diet alone. Eligible subjects will be asked to provide informed written consent, and studies will be undertaken in accordance with the Declaration of Helsinki.

•Any co-morbid conditions requiring drug therapy that cannot be discontinued, any regular drug treatment that cannot be discontinued, any diseases of the heart, lungs, liver, gut or endocrine glands, alcoholism, eating disorder, and for the diabetic group - poorly controlled diabetes (defined as HbAlc >8.0% for the purposes of this study)

发起方

Record Provided by the NHSTCT Register - 2006 Update - Department of Health